CD19 Matched Antibody Pair (208) (APMAB-208LY)

Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., ... & Miklos, D. B. (2021). CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine, 27(8), 1419-1431.

Nerreter, T., Letschert, S., Götz, R., Doose, S., Danhof, S., Einsele, H., ... & Hudecek, M. (2019). Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T. Nature communications, 10(1), 1-11.

Ying, Z., Huang, X. F., Xiang, X., Liu, Y., Kang, X., Song, Y., ... & Chen, S. Y. (2019). A safe and potent anti-CD19 CAR T cell therapy. Nature medicine, 25(6), 947-953.

Hatterer, E., Barba, L., Noraz, N., Daubeuf, B., Aubry-Lachainaye, J. P., von der Weid, B., ... & Buatois, V. (2019, February). Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation. In MAbs (Vol. 11, No. 2, pp. 322-334). Taylor & Francis.

Salter, A. I., Pont, M. J., & Riddell, S. R. (2018). Chimeric antigen receptor–modified T cells: CD19 and the road beyond. Blood, The Journal of the American Society of Hematology, 131(24), 2621-2629.

Bagashev, A., Sotillo, E., Tang, C. H. A., Black, K. L., Perazzelli, J., Seeholzer, S. H., ... & Thomas-Tikhonenko, A. (2018). CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum. Molecular and cellular biology, 38(21), e00383-18.

Turtle, C. J., Hay, K. A., Hanafi, L. A., Li, D., Cherian, S., Chen, X., ... & Maloney, D. G. (2017). Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor–modified T cells after failure of ibrutinib. Journal of Clinical Oncology, 35(26), 3010.

Alabanza, L., Pegues, M., Geldres, C., Shi, V., Wiltzius, J. J., Sievers, S. A., ... & Kochenderfer, J. N. (2017). Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Molecular Therapy, 25(11), 2452-2465.

Li, X., Ding, Y., Zi, M., Sun, L., Zhang, W., Chen, S., & Xu, Y. (2017). CD19, from bench to bedside. Immunology letters, 183, 86-95.

Liu, L., Lam, C. Y. K., Long, V., Widjaja, L., Yang, Y., Li, H., ... & Bonvini, E. (2017). MGD011, A CD19 x CD3 dual-affinity retargeting bi-specific molecule incorporating extended circulating half-life for the treatment of B-cell malignancies. Clinical Cancer Research, 23(6), 1506-1518.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Alternative Versions

CD19 Matched Antibody Pair (207)

Antibody Pairs

CD19 Matched Antibody Pair (207)

Related Products

Mouse Anti-CD19 Recombinant Antibody (CB19)

Rat Anti-CD19 Recombinant Antibody (6OMP31)

Mouse Anti-CD19 Recombinant Antibody (CAP381)

Rat Anti-CD19 Recombinant Antibody (CBYY-C1207)

Mouse Anti-CD19 Recombinant Antibody (HD37)

Mouse Anti-CD19 Recombinant Antibody (5B14)

Mouse Anti-CD19 Recombinant Antibody (CBFYC-0408)

Mouse Anti-CD19 Recombinant Antibody (13B117)

Rat Anti-CD19 Recombinant Antibody (CBYY-C0553)

Mouse Anti-CD19 Recombinant Antibody (CB30A)

Isotype control